Latest news with #JunshiBiosciences
Toronto Star
2 days ago
- Business
- Toronto Star
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application ('sNDA') for toripalimab (trade name: TUOYI®) in combination with disitamab vedotin, an antibody-drug conjugate ('ADC') developed by RemeGen Co., Ltd. as the treatment of HER2-expressing (HER2 expression is defined as a HER2 immunohistochemistry test result of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma ('UC'), has been accepted by the National Medical Products Administration ('NMPA'). This is toripalimab's 13th application for marketing submitted in the Chinese mainland. UC is one of the ten most prevalent malignant tumors in the world, and in China, its incidence and mortality rates continue rising annually. According to the latest data from the National Cancer Center, in 2022, the number of new cases of UC in China reached 92,900, and the number of deaths reached over 40,000. UC is a serious threat to the life and health of patients, and there are huge unmet clinical needs.
Bloomberg
19-05-2025
- Business
- Bloomberg
Covid Test, Vaccine Maker Stocks Jump as Cases Surge in Asia
Shares of Covid test kit and drug makers in Asia rose following a surge of cases. South Korean diagnostic kit maker Sugentech Inc. was among the top performers, jumping as much as 29% on Monday. In Japan, shares of Covid vaccine maker Daiichi Sankyo rose as much as 7.4% after its price target was raised at UBS. In Hong Kong, shares of Shanghai Junshi Biosciences Co., which also makes Covid jabs, gained as much as 4.3%.
